Thomas Ebenhan, Elena Lazzeri and Olivier Gheysens* Pages 772 - 786 ( 15 )
Infectious diseases remain a major health problem and cause of death worldwide. It is expected that the socio-economic impact will further intensify due to escalating resistance to antibiotics, an ageing population and an increase in the number of patients under immunosuppressive therapy and implanted medical devices. Even though radiolabeled probes and leukocytes are routinely used in clinical practice, it might still be difficult to distinguish sterile inflammation from inflammation caused by bacteria. Moreover, the majority of these probes are based on the attraction of leukocytes which may be hampered in neutropenic patients. Novel approaches that can be implemented in clinical practice and allow for swift diagnosis of infection by targeting the microorganism directly, are posing an attractive strategy. Here we review the current strategies to directly image bacteria using radionuclides and we provide an overview of the preclinical efforts to develop and validate new approaches. Indeed, significant progress has been made in the past years, but very few radiopharmaceuticals (that were promising in preclinical studies) have made it into clinical practice. We will discuss the challenges that remain to select good candidates for imaging agents targeting bacteria.
Radionuclide imaging, bacterial infection, antimicrobial peptides, radiolabeled leukocytes, biomimetics, antibiotics.
Nuclear Medicine at Steve Biko Academic Hospital, University of Pretoria, Pretoria, Nuclear Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven